IPOX 100 U.S. (ETF: FPX) jumps, outpaces all U.S. markets. Strong gains extend to IPOX International (ETF: FPXI), IPOX Europe (ETF: FPXE) as recent IPOs surge. U.S. yields rise. Amid a jump in U.S. yields, stable risk (VIX: +0.44%) and big divergence in portfolio returns after earnings, the IPOX Indexes continued to gain last week. In the U.S., e.g., the IPOX 100 U.S. (ETF: FPX) added +1.32% to +17.87% YTD, outpacing the major U.S. benchmarks and extending the lead vs. the S&P 500 (SPX) to +603 bps. YTD. Amid more M&A by big pharma, e.g., gains in specialty holdings drove the good showing in the IPOX 100 U.S. (ETF: FPX), including 10/18 IPO biotech Guardant Health (GH US: +30.41%), e-commerce platform operator Etsy (ETSY US: +28.41%) or security software market Zscaler (ZS US: +21.68%). Friday’s plunge in cloud computing software maker Nutanix (NTNX US: -36.51%) after earnings somewhat dented positive sentiment towards the week-end. Abroad, we note another solid showing in the IPOX International (ETF: FPXI) and IPOX Europe (ETF: FPXE) which far outpaced the regional benchmarks anew, with performance driven by explosive moves in select specialty holdings including 09/18 IPO ecommerce platform operator apparel retailer London-based Farfetch (FTCH US: +42.67%) or Chinese electric car maker NIO (NIO US: +23.13%) after earnings or significant U.S. media coverage. As earnings season comes to a close, 5.01% of the weight in the IPOX 100 U.S. (ETF: FPX) is set to report this week.
IPOX® 100 U.S. Investing with the “FPX” ETF since 2006
IPOX-linked Products Performance Updates: The IPOX 100 U.S. (IPXO)-linked, 5-star $1.1 billion First Trust U.S. Equity Opportunities ETF (FPX) added +1.34% to +18.00% YTD, while the IPOX International (IPXI)-linked 5-star First Trust International Equity Opportunities ETF (FPXI) added +1.11% to +15.12% YTD and the IPOX 100 Europe (IPOE)-linked First Trust IPOX® Europe Equity Opportunities ETF (FPXE) added +1.83% to close the week at +14.29% YTD. Amongst actively managed mutual funds, the Catalyst IPOX Allocation Fund (OIPAX) rose to +16.65% YTD.
|IPOX® Indexes Price Returns (%) (RT)||Last Weerk||2018||2019 YTD|
|IPOX® Indexes: Global/International|
|IPOX® Global (IPGL50) (USD)||1.28||-11.37||16.95|
|IPOX® International (IPXI)* (USD)||1.07||-13.41||14.12|
|IPOX® Indexes: United States|
|IPOX® Comp. U.S. (IPXC)*||1.52||-7.59||17.71|
|IPOX® 100 U.S. (IPXO)*||1.32||-8.80||17.87|
|IPOX® 30 U.S. (IPXT)||1.12||-10.28||14.38|
|IPOX® Indexes: Europe/Nordic|
|IPOX® 30 Europe (IXTE) (EUR)||0.85||-13.46||12.34|
|IPOX® Nordic (IPND)||0.77||-15.45||12.48|
|IPOX® 100 Europe (IPOE)* (USD)||1.55||-16.60||12.37|
|IPOX® Indexes: Asia-Pacific/China|
|IPOX® Asia-Pacific (IPTA) (USD)||0.53||-3.21||3.93|
|IPOX® China (CNI) (USD)||2.20||-22.83||21.63|
|IPOX® Japan (IPJP)** (JPY)||0.98||-13.70||6.37|
* Basis for ETFs: FPX US, FPX LN, FPXE US, FPXU FP, FPXI US, TCIP110 IT and CME-traded e-mini IPOX® 100 U.S. Futures (IPOH9). ** Live since 07/18. Please contact [email protected] for other IPOX® Indexes.
IPO Deal-flow Review & Outlook: Global IPO market regains momentum. Tencent-backed Chinese online brokerage Futu ready for debut. Four firms debuted last week across accessible global regions, with the average (median) equally-weighted firm declining by -2.82% (-0.59%) based on the difference between the final offer price and Friday’s close. Priced far below its initial range, VC-incubated Kaleido (KLDO US: -1.53%) declined, while GIC-backed biotech startup CStone Pharmaceuticals (2616 HK: +8.17%) rose and U.S. ride sharer Lyft disclosed financial terms related to its pending IPO. Backed by Chinese internet-behemoth Tencent and VC funds Sequoia and Matrix Partners, Hong Kong-based online brokerage Futu (FHL US) is set to launch its IPO this week.
February IPO Market Recap: 20 sizable companies went public in the accessible global markets last month, a decline of 37.5% compared to 2018. With IPO deal flow affected by the U.S. government shutdown, IPOs in the U.S. still ranked on top according to both deal-count and proceeds raised as cash-hungry small biotechs led the way with 9 firms (8 biotechs) debuting, raising USD million 948. Amongst firms postponed or withdrawn, Fortress and Branson-backed high-profile Virgin Trains ranked on top. Abroad, Hong Kong saw a slowdown due to the Chinese New Year and weak aftermarket performance, yet secured 3 sizeable launches that raised USD million 725 in total, while the European IPO market remained closed amid Brexit. With a valuation of USD billion 1.5, HK-traded biopharma CStone (2616 HK) raised USD million 285, making it the largest IPO in February. Another immunotherapy firm, US-traded TCR2 Therapeutics (TCRR US), ranked as the best performer of the month with a +42.73% surge based on its 1st close.
|Select IPOs traded (week: 02/25/2019)||Domicile|
|Kaleido Biosciences Inc|
|Select IPOs expected (week: 03/04/2019)||Domicile|
|Futu Holdings Ltd||China|
Lime Brokerage LLC is not affiliated with these service providers. Data, information, and material (“content”) is provided for informational and educational purposes only. This content neither is, nor should be construed as an offer, solicitation, or recommendation to buy or sell any securities. Any investment decisions made by the user through the use of such content is solely based on the users independent analysis taking into consideration your financial circumstances, investment objectives, and risk tolerance. Lime Brokerage LLC does not endorse, offer or recommend any of the services nor information provided by any of the above service providers and any service or information used to execute any trading strategies are solely based on the independent analysis of the user.